Deregulation of microRNAs in myelodysplastic syndrome

Leukemia

Volumn 26, Issue 1, 2012, Pages 13-22

  Rhyasen, G W ^a   Starczynowski, D T ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

microarray; microRNA; myelodysplastic syndrome

Indexed keywords

DICER; MICRORNA; MICRORNA 125; MICRORNA 145; MICRORNA 146A; UNCLASSIFIED DRUG;

DOWN REGULATION; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HIGH THROUGHPUT SEQUENCING; HUMAN; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 84856709581     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.221     Document Type: Review

References (83)

1. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118-129. (Pubitemid 46164747)
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088. (Pubitemid 27132124)
3. Cazzola M, Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am 2010; 24: 459-468.
4. Nilsson L, Eden P, Olsson E, Mansson R, Astrand-Grundstrom I, Strombeck B et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 2007; 110: 3005-3014. (Pubitemid 350006955)
5. Nilsson L, Astrand-Grundstrom I, Arvidsson I, Jacobsson B, Hellstrom-Lindberg E, Hast R et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000; 96: 2012-2021.
6. Tiu R, Gondek L, O'Keefe C, Maciejewski JP. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia 2007; 21: 1648-1657. (Pubitemid 47086755)
7. Guidetti F, Grazioli S, Capelli F, Marini C, Gallicchio M, De Micheli D et al. Primitive hematopoietic stem cells shows a polyclonal pattern in myelodysplastic syndromes. Haematologica 2004; 89: 21-28. (Pubitemid 38165851)
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
9. Djuranovic S, Nahvi A, Green R. A parsimonious model for gene regulation by miRNAs. Science 2011; 331: 550-553.
10. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-1934.
11. Khraiwesh B, Arif MA, Seumel GI, Ossowski S, Weigel D, Reski R et al. Transcriptional control of gene expression by microRNAs. Cell 2011; 140: 111-122.
12. Cissell KA, Deo SK. Trends in microRNA detection. Anal Bioanal Chem 2009; 394: 1109-1116.
13. Schotte D, Moqadam FA, Lange-Turenhout EA, Chen C, van Ijcken WF, Pieters R et al. Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. Leukemia 2011; in press.
14. Morin RD, O'Connor MD, Griffith M, Kuchenbauer F, Delaney A, Prabhu AL et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res 2008; 18: 610-621. (Pubitemid 351482785)
15. Petriv OI, Kuchenbauer F, Delaney AD, Lecault V, White A, Kent D et al. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci USA 2010; 107: 15443-15448.
16. Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci USA 2010; 107: 14229-14234.
17. Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008; 132: 860-874. (Pubitemid 351312808)
18. Cobb BS, Hertweck A, Smith J, O'Connor E, Graf D, Cook T et al. A role for Dicer in immune regulation. J Exp Med 2006; 203: 2519-2527. (Pubitemid 44664621)
19. Navarro F, Lieberman J. Small RNAs guide hematopoietic cell differentiation and function. J Immunol 2010; 184: 5939-5947.
20. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9: 839-845. (Pubitemid 352038302)
21. Georgantas III RW, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750-2755. (Pubitemid 46327951)
22. Liao R, Sun J, Zhang L, Lou G, Chen M, Zhou D et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem 2008; 104: 805-817. (Pubitemid 351830831)
23. Ooi AG, Sahoo D, Adorno M, Wang Y, Weissman IL, Park CY. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci USA 2011; 107: 21505-21510.
24. Merkerova M, Vasikova A, Belickova M, Bruchova H. MicroRNA expression profiles in umbilical cord blood cell lineages. Stem Cells Dev 2010; 19: 17-26.
25. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004. (Pubitemid 38327724)
26. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838. (Pubitemid 40839735)
27. Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J et al. Genome-wide identification of human micro-RNAs located in leukemia-associated genomic alterations. Blood 2011; 117: 595-607.
28. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529. (Pubitemid 35403967)
29. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-13949. (Pubitemid 41377683)
30. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
31. Eyholzer M, Schmid S, Schardt JA, Haefliger S, Mueller BU, Pabst T. Complexity of miR-223 regulation by CEBPA in human AML. Leuk Res 2010; 34: 672-676.
32. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105: 3945-3950. (Pubitemid 351723504)
33. Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol 2010; 85: 331-339.
34. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1919-1928. (Pubitemid 351620112)
35. Hussein K, Theophile K, Busche G, Schlegelberger B, Gohring G, Kreipe H et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 2010; 34: 1169-1174.
36. Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 2011; 153: 24-32.
37. Erdogan B, Facey C, Qualtieri J, Tedesco J, Rinker E, Ben Isett R et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 2011; in press.
38. Dostalova Merkerova M, Krejcik Z, Votavova H, Belickova M, Vasikova A, Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011; 19: 313-319.
39. Votavova H, Grmanova M, Dostalova Merkerova M, Belickova M, Vasikova A, Neuwirtova R et al. Differential expression of microRNAs in CD34+ cells of 5q-syndrome. J Hematol Oncol 2010; 4: 1.
40. Hussein K, Busche G, Muth M, Gohring G, Kreipe H, Bock O. Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. Ann Hematol 2010; 90: 307-313.
41. Pons A, Nomdedeu B, Navarro A, Gaya A, Gel B, Diaz T et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma 2009; 50: 1854-1859.
42. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med 2010; 16: 49-58.
43. Oliva EN, Nobile F, Iacopino P, Alimena G, Raimondo FD, Palumbo GA et al. Increases in Mirna-145 and Mirna-146a Expression in Patients with IPSS Lower-Risk Myelodysplastic Syndromes and Del(5q) Treated with Lenalidomide. American Society of Hematology: Orlando, FL, 2010.
44. Kumar M, Narla A, Nonami A, Ball B, Chin C, Chen C et al. Coordinate Loss of a MicroRNA Mir 145 and a Protein-Coding Gene RPS14 Cooperate in the Pathogenesis of 5q-Syndrome. American Society of Hematology: New Orleans, LA, 2009.
45. Boultwood J, Pellagatti A, Cattan H, Lawrie CH, Giagounidis A, Malcovati L et al. Gene expression profiling of CD34+ cells in patients with the 5q-syndrome. Br J Haematol 2007; 139: 578-589. (Pubitemid 350043812)
46. Hussein K, Theophile K, Busche G, Schlegelberger B, Gohring G, Kreipe H et al. Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk Res 2010; 34: 328-334.
47. Metcalf D, Carpinelli MR, Hyland C, Mifsud S, Dirago L, Nicola NA et al. Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene. Blood 2005; 105: 3480-3487. (Pubitemid 40628189)
48. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008; 205: 2499-2506.
49. Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008; 112: 3412-3424.
50. Mohamedali A, Gaken J, Twine NA, Ingram W, Westwood N, Lea NC et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365-3373. (Pubitemid 350106331)
51. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008; 111: 1534-1542. (Pubitemid 351213443)
52. Stephenson J, Czepulkowski B, Hirst W, Mufti GJ. Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Leuk Res 1996; 20: 235-241. (Pubitemid 26144140)
53. Le Beau MM, Espinosa III R, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996; 88: 1930-1935. (Pubitemid 26307892)
54. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome-components and functional correlates. Genes Dev 2006; 20: 3215-3231.
55. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
56. Steensma DP, Stone RM. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am 2010; 24: 389-406.
57. Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010; 24: 317-330.
58. Meng Y, Xia Q, Hu J. Promoter Methylation and Decreased Expression of Mir-124 in Myelodysplastic Syndromes. American Society of Hematology: Orlando, FL, 2010.
59. Dickstein J, Senyuk V, Premanand K, Laricchia-Robbio L, Xu P, Cattaneo F et al. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci USA 2010; 107: 9783-9788.
60. Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010; 56: 998-1006.
61. Zuo Z, Calin GA, de Paula HM, Medeiros LJ, Fernandez MH, Shimizu M et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 2011; 118: 413-415.
62. Facey C, Isett RB, Tobias J, Baldwin DA, Thompson JE, Carroll M et al. MicroRNA Diagnostic Signature of Myelodysplastic Syndrome. American Society of Hematology: New Orleans, LA, 2009.
63. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465. (Pubitemid 44511560)
64. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-557. (Pubitemid 40204668)
65. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008; 451: 335-339.
66. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med 2010; 16: 59-66.
67. Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA 2007; 104: 11406-11411. (Pubitemid 47175153)
68. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974-12979.
69. Venner CP, List A, Nevill TJ, Deeg HJ, Caceres G, Scott BL et al. Induction of Micro RNA-143 and 145 in Pre-Treatment CD34+ Cells From Patients with Myelodysplastic Syndrome (MDS) After in Vitro exposure to Lenalidomide Correlates with Clinical Response in Patients Harboring the Del5q Abnormality. American Society of Hematology: Orlando, FL, 2010.
70. Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 2007; 121: 64-73. (Pubitemid 47126065)
71. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852-857.
72. Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villaron EM, Hernandez-Campo P et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia 2009; 23: 664-672.
73. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-12486. (Pubitemid 44267285)
74. Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL et al. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp Hematol 2010; 39: 167-178, e4.
75. Starczynowski DT, Karsan A. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle 2010; 9: 855-856.
76. Starczynowski DT, Karsan A. Innate immune signaling in the myelodysplastic syndromes. Hematol Oncol Clin North Am 2010; 24: 343-359.
77. Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, Petrucci E et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol 2008; 10: 788-801. (Pubitemid 351927708)
78. Opalinska JB, Bersenev A, Zhang Z, Schmaier AA, Choi J, Yao Y et al. MicroRNA expression in maturing murine megakaryocytes. Blood 2010; 116: e128-e138.
79. Zhao JL, Rao DS, Boldin MP, Taganov KD, O'Connell RM, Baltimore D. NF-{kappa}B dysregulation in microRNA-146adeficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 2011; 108: 9184-9189.
80. Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010; 142: 914-929.
81. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011; 208: 1189-1201.
82. O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci USA 2010; 107: 14235-14240.
83. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008; 455: 64-71.